Key Highlights

  • Shares traded at $0.360, up 9.09%, during the Trading session on 30 October 2026.
  • Arrotex will hold exclusive commercialisation rights for R327G in Australia and New Zealand, with no upfront or milestone payments.
  • Recce will receive a profit share on Arrotex's gross Margin from R327G sales and will remain the exclusive manufacturer and supplier.

Recce Pharmaceuticals Ltd (ASX:RCE) shares traded at $0.360 during the trading session on 30 October 2026, rising 9.09%. The S&P/ASX 200 (ASX:XJO) stood at 8,973.00, up 0.91% or 81.20 points at 11:15 am. Recce is a clinical-stage biotechnology company developing synthetic anti-infectives, with its lead candidate RECCE 327 in registrational Phase 3 development for diabetic foot infections. The company's agreement with Arrotex Pharmaceuticals was announced on 22 October 2026, eight days before the share move, so the two are discussed separately.

Latest Development: Arrotex Licence (22 October 2026)

Recce and Arrotex Pharmaceuticals Pty Ltd entered into an exclusive licence and commercialisation agreement for Arrotex to register and commercialise R327G, the topical gel formulation of RECCE 327, for diabetic foot infections in Australia and New Zealand. The agreement is described as binding and not subject to any conditions precedent. The licensed indications also include acute bacterial skin and skin structure infections.

Recce will receive a profit share of the gross margin on Arrotex's sales, calculated as net sales less Recce's cost of goods, paid quarterly. Arrotex will bear all commercialisation costs in the territory, including regulatory filings and Pharmaceutical Benefits Scheme and Pharmac submissions.

Terms, Exclusivity and Regulatory Path

Recce retains ownership of all intellectual property, rights outside the territory and the right to conduct Clinical Trials in the territory. It will continue to fund global clinical development, Manufacturing and regulatory filings outside Australia and New Zealand.

Arrotex is required to apply for Therapeutic Goods Administration approval only after R327G is approved by the United States Food and Drug Administration, the European Medicines Agency or another comparable overseas regulator. The release notes that R327G remains investigational and has not been approved for commercial use in Australia, New Zealand or the United States.

Sector Context

Diabetic foot infections are bacterial infections that can lead to hospitalisation, surgery or amputation, and they are often difficult to treat because of impaired circulation and antimicrobial resistance. The release estimates that about 50,000 Australians are living with a diabetes-related foot ulcer, with a further 300,000 considered at risk. Companies developing treatments for antibiotic-resistant infections work within a regulatory framework that requires clinical data before market approval.

Risks

Availability of R327G in Australia and New Zealand is subject to successful completion of clinical development and regulatory approval, as the release states. Recce's profit share depends on Arrotex's sales and on the gross margin achieved. The agreement may be terminated in certain circumstances, including if Recce discontinues its overseas regulatory pathway. The product is at Phase 3 stage and its outcome cannot be assumed.

What Lies Ahead

The product will continue through registrational Phase 3 development. The company's future announcements are expected to address the clinical program, the overseas regulatory pathway and any progress toward Therapeutic Goods Administration applications.

Final Word

Recce's shares rose 9.09% during the 30 October 2026 session, eight days after the company announced an exclusive licence with Arrotex for R327G in Australia and New Zealand. The agreement sets out a profit-sharing structure in which Arrotex takes on commercialisation costs, and its effect will depend on clinical and regulatory progress.